TCGX Acquisition Corp. names Daniel Lynch as Chairman of TriGemX Bio's Board, enhancing leadership ahead of the anticipated merger.
| Name | TCGX Acquisition Corp. |
|---|---|
| CIK | 0002137965 |
| Tickers | TCGX |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company |
| SIC | 6770 Blank Checks |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | E9 Cayman Islands |
| Phone | (415) 260-2047 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
TCGX Acquisition Corp. names Daniel Lynch as Chairman of TriGemX Bio's Board, enhancing leadership ahead of the anticipated merger.
TCGX Acquisition Corp. announces progress on its merger with TriGemX Bio, a move that could reshape its future in the biotechnology sector.
TCGX Acquisition Corp. is set to merge with TriGemX Bio, valued at $600 million, to advance a new migraine treatment. The deal highlights SPAC trends in biotech.
TCGX Acquisition Corp. announces a proposed business combination with TriGemX Bio, signaling a key move in the blank check company sector.
TCGX Acquisition Corp. is set to merge with TriGemX Bio, marking a strategic shift towards the life sciences sector. The merger is expected to close in early 2027.
29 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-128726 | 005-95867 | 261563801 | 34 | 14633 | |||
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-464039 | 005-95867 | 261563394 | 34 | 121141 | |||
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-007955 | 005-95867 | 261555984 | 34 | 14987 | |||
| 2026-11-09 | 10-Q | 10-Q | 0001193125-26-453559 | 001-43434 | 261535881 | 34 | 5005755 | 1 | 1 | |
| 2026-11-09 | 425 | 425 | 0001193125-26-452777 | 001-43434 | 261534115 | 34 | 22272 | |||
| 2026-11-02 | 425 | 425 | 0001193125-26-443618 | 001-43434 | 261512228 | 34 | 21123 | |||
| 2026-10-19 | 425 | 425 | 0001193125-26-425374 | 001-43434 | 261469857 | 34 | 135148 | |||
| 2026-10-19 | 425 | 425 | 0001193125-26-425370 | 001-43434 | 261469852 | 34 | 22765 | |||
| 2026-10-19 | 425 | 425 | 0001193125-26-424760 | 001-43434 | 261467711 | 34 | 5869412 | |||
| 2026-10-19 | 8-K | 8-K | 1.01,3.02,7.01,9.01 | 0001193125-26-424754 | 001-43434 | 261467699 | 34 | 6374170 | 1 | 1 |
| 2026-09-10 | 10-Q | 10-Q | 0001193125-26-387873 | 001-43434 | 261371159 | 34 | 3225404 | 1 | 1 | |
| 2026-08-13 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001346824-26-000226 | 005-95867 | 261273581 | 34 | 18963 | |||
| 2026-08-12 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000921895-26-002072 | 005-95867 | 261268413 | 34 | 38512 | |||
| 2026-08-12 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-347043 | 001-43434 | 261268292 | 34 | 248589 | 1 | 1 |
| 2026-08-06 | 4 | 4 | 0001193125-26-338403 | 7059 | ||||||
| 2026-08-06 | 3/A | 3/A | 0001193125-26-338388 | 7358 | ||||||
| 2026-08-06 | 8-K | 8-K | 1.01,3.02,5.02,5.03,8.01,9.01 | 0001193125-26-338268 | 001-43434 | 261249793 | 34 | 1334591 | 1 | 1 |
| 2026-08-06 | 424B4 | 424B4 | 0001193125-26-336098 | 333-297569 | 261245532 | 33 | 1658578 | |||
| 2026-08-04 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-002536 | 333-297569 | 261241080 | 33 | 1907 | ||
| 2026-08-04 | 3 | 3 | 0001193125-26-333338 | 19733 | ||||||
| 2026-08-04 | 3 | 3 | 0001193125-26-333337 | 21514 | ||||||
| 2026-08-04 | 3 | 3 | 0001193125-26-333336 | 21351 | ||||||
| 2026-08-04 | 3 | 3 | 0001193125-26-333335 | 20969 | ||||||
| 2026-08-04 | 3 | 3 | 0001193125-26-333334 | 21310 | ||||||
| 2026-08-04 | CERT | 8A_CERT_TCGX_0002137965.pdf | 0001354457-26-000754 | 001-43434 | 261237784 | 34 | 181606 | |||
| 2026-08-04 | 8-A12B | 8-A12B | 0001193125-26-332291 | 001-43434 | 261237153 | 34 | 14128 | |||
| 2026-07-31 | S-1/A | S-1/A | 0001193125-26-328576 | 333-297569 | 261228608 | 33 | 108845 | |||
| 2026-07-20 | S-1 | S-1 | 0001193125-26-308950 | 333-297569 | 261187005 | 33 | 5059614 | 1 | 1 | |
| 2026-06-23 | DRS | filename1.htm | 0001193125-26-278885 | 377-09499 | 261109943 | 33 | 1711375 |
One latest value per concept from companyfacts (59 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ffd | NetFeeAmt | NetFeeAmt | USD | 11,911.13 | 2026-07-20 | S-1 | 2026-07-20 | 0001193125-26-308950 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 11,911.13 | 2026-07-20 | S-1 | 2026-07-20 | 0001193125-26-308950 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 86.25M | 2026-07-20 | S-1 | 2026-07-20 | 0001193125-26-308950 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-07-20 | S-1 | 2026-07-20 | 0001193125-26-308950 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-07-20 | S-1 | 2026-07-20 | 0001193125-26-308950 | |||
| us-gaap | AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent | Accounts Payable and Accrued Liabilities | USD | 295,977 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 6,012 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-10 | 0001193125-26-387873 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | Assets | Assets | USD | 89.72M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 2.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | AssetsHeldInTrustCurrent | Assets Held-in-trust, Current | USD | 86.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | AssetsHeldInTrustNoncurrent | Assets Held-in-trust, Noncurrent | USD | 86.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | Cash | Cash | USD | 2.67M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 2.67M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | USD | 2.67M | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | CashFDICInsuredAmount | Cash, FDIC Insured Amount | USD | 250,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | DeferredCosts | Deferred Costs, Noncurrent | USD | 246,383 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-10 | 0001193125-26-387873 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 3.45M | 2026-08-06 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -0.04 | 2026-05-26 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-10 | 0001193125-26-387873 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -0.04 | 2026-05-26 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-10 | 0001193125-26-387873 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 526,749 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | IncreaseDecreaseInAccountsPayableAndAccruedLiabilities | Increase (Decrease) in Accounts Payable and Accrued Liabilities | USD | 270,796 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 6,012 | 2026-05-26 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-10 | 0001193125-26-387873 |
| us-gaap | IncreaseDecreaseInPrepaidExpense | Increase (Decrease) in Prepaid Expense | USD | -22,500 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | InterestIncomeOther | Interest Income, Other | USD | 483,311 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 483,311 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | Liabilities | Liabilities | USD | 4.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 89.72M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 648,979 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 89.29M | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -86.25M | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -365,569 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -43,438 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 483,311 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -526,749 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | OtherDeferredCostsNet | Other Deferred Costs, Net | USD | 662,054 | 2026-08-06 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | OtherLiabilitiesCurrent | Other Liabilities, Current | USD | 32,232 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 462,086 | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | PaymentsToAcquireInvestments | Payments to Acquire Investments | USD | 86.25M | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 1.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | PrepaidExpenseCurrent | Prepaid Expense, Current | USD | 102,500 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | PrepaidExpenseNoncurrent | Prepaid Expense, Noncurrent | USD | 95,605 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 86.25M | 2026-08-06 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 84.53M | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 5.22M | 2026-05-26 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -1.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | -1.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 25,000 | 2026-05-26 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | TemporaryEquityAccretionToRedemptionValue | Temporary Equity, Accretion to Redemption Value | USD | 6.28M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 86.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | TemporaryEquityRedemptionPricePerShare | Temporary Equity, Redemption Price Per Share | USD/shares | 10.06 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 8.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-09 | 0001193125-26-453559 | |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 1.88M | 2026-05-26 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-10 | 0001193125-26-387873 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 1.88M | 2026-05-26 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-10 | 0001193125-26-387873 |